Clinical prospective study of Gallium 68 (68Ga)-labeled fibroblast-activation protein inhibitor PET/CT in the diagnosis of biliary tract carcinoma

被引:13
|
作者
Li, Jinghua [1 ,2 ]
Xu, Kui [3 ]
Guo, Deliang [1 ,2 ]
Liao, Bo [1 ,2 ]
Zhu, Qian [1 ,2 ]
Wang, Haitao [1 ,2 ]
Jiang, Yaqun [2 ,3 ]
Wu, Dongde [4 ]
Xia, Xigang [5 ]
Jiang, Ping [1 ,2 ]
Tang, Shengli [1 ,2 ]
Yang, Zhiyong [1 ,2 ]
He, Yueming [1 ,2 ]
Zhang, Zhonglin [1 ,2 ]
He, Yong [2 ,3 ]
Yuan, Yufeng [1 ,2 ,6 ]
机构
[1] Wuhan Univ, Dept Hepatobiliary & Pancreat Surg, Zhongnan Hosp, Wuhan, Hubei, Peoples R China
[2] Clin Med Res Ctr Minimally Invas Procedure Hepatob, Wuhan, Hubei, Peoples R China
[3] Wuhan Univ, Dept Nucl Med, Zhongnan Hosp, Wuhan, Hubei, Peoples R China
[4] Huazhong Univ Sci & Technol, Hubei Canc Hosp, Tongji Med Coll, Dept Hepatobiliary & Pancreat Surg, Wuhan, Hubei, Peoples R China
[5] Jingzhou Cent Hosp, Dept Hepatobiliary Surg, Jingzhou, Hubei, Peoples R China
[6] Wuhan Univ, TaiKang Ctr Life & Med Sci, Wuhan, Hubei, Peoples R China
关键词
Fibroblast activation protein; FAPI; PET/CT; Biliary tract carcinoma; CANCER-ASSOCIATED FIBROBLASTS; F-18-FDG; MANAGEMENT;
D O I
10.1007/s00259-023-06137-z
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
PurposeThis study is to investigate the [Ga-68]Ga-DOTA-FAPI PET/CT diagnosis performance in biliary tract carcinoma (BTC) and analyze the association between [Ga-68]Ga-DOTA-FAPI PET/CT and clinical indexes. Methods A prospective study (NCT 05264688) was performed between January 2022 and July 2022. Fifty participants were scanned using [Ga-68]Ga-DOTA-FAPI and [F-18]FDG PET/CT and acquired pathological tissue. We employed the Wilcoxon signed-rank test to compare the uptake of [Ga-68]Ga-DOTA-FAPI and [F-18]FDG, and the McNemar test was used to compare the diagnostic efficacy between the two tracers. Spearman or Pearson correlation was used to assess the association between [(68) Ga]Ga-DOTA-FAPI PET/CT and clinical indexes. Results In total, 47 participants (mean age 59.09 +/- 10.98 [range 33-80 years]) were evaluated. The [Ga-68]Ga-DOTA-FAPI detection rate was greater than [F-18]FDG in primary tumors (97.62% vs. 85.71%), nodal metastases (90.05% vs. 87.06%), and distant metastases (100% vs. 83.67%). The uptake of [Ga-68]Ga-DOTA-FAPI was higher than [F-18]FDG in primary lesions (intrahepatic cholangiocarcinoma, 18.95 +/- 7.47 vs. 11.86 +/- 0.70, p = 0.001; extrahepatic cholangiocarcinoma, 14.57 +/- 6.16 vs. 8.80 +/- 4.74, p = 0.004), abdomen and pelvic cavity nodal metastases (6.91 +/- 6.56 vs. 3.94 +/- 2.83, p < 0.001), and distant metastases (pleural, peritoneum, omentum, and mesentery, 6.37 +/- 4.21 vs. 4.50 +/- 1.96, p = 0.01; bone, 12.15 +/- 6.43 vs. 7.51 +/- 4.54, p = 0.008). There was a significant correlation between [Ga-68]Ga-DOTA-FAPI uptake and fibroblast-activation protein (FAP) expression (Spearman r = 0.432, p = 0.009), carcinoembryonic antigen (CEA) (Pearson r = 0.364, p = 0.012), and platelet (PLT) (Pearson r = 0.35, p = 0.016). Meanwhile, a significant relationship between [Ga-68]Ga-DOTA-FAPI metabolic tumor volume and carbohydrate antigen199 (CA199) (Pearson r = 0.436, p = 0.002) was confirmed. Conclusion [Ga-68]Ga-DOTA-FAPI had a higher uptake and sensitivity than [F-18]FDG in the diagnosis of BTC primary and metastatic lesions. The correlation between [Ga-68]Ga-DOTA-FAPI PET/CT indexes and FAP expression, CEA, PLT, and CA199 were confirmed.
引用
收藏
页码:2152 / 2166
页数:15
相关论文
共 47 条
  • [1] Clinical prospective study of Gallium 68 (68Ga)–labeled fibroblast-activation protein inhibitor PET/CT in the diagnosis of biliary tract carcinoma
    Li Jinghua
    Xu Kui
    Guo Deliang
    Liao Bo
    Zhu Qian
    Wang Haitao
    Jiang Yaqun
    Wu Dongde
    Xia Xigang
    Jiang Ping
    Tang Shengli
    Yang Zhiyong
    He Yueming
    Zhang Zhonglin
    He Yong
    Yuan Yufeng
    European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50 : 2152 - 2166
  • [2] A pilot study of [68Ga]Ga-fibroblast activation protein inhibitor-04 PET/CT in renal cell carcinoma
    Guo, Chunmei
    Liu, Ya
    Yang, Haozhou
    Xia, Yuxiao
    Li, Xue
    Chen, Liming
    Feng, Yue
    Zhang, Yan
    Chen, Yue
    Huang, Zhanwen
    BRITISH JOURNAL OF RADIOLOGY, 2024, 97 (1156) : 859 - 867
  • [3] Gallium-68-labeled fibroblast activation protein inhibitor PET in gastrointestinal cancer: insights into diagnosis and management
    Chunxia Qin
    Yangmeihui Song
    Yongkang Gai
    Weiwei Ruan
    Qingyao Liu
    Fang Liu
    Danzha Zheng
    Peng Zhang
    Hongli Liu
    Tao Zhang
    Kaixiong Tao
    Xiaoli Lan
    European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49 : 4228 - 4240
  • [4] Gallium-68-labeled fibroblast activation protein inhibitor PET in gastrointestinal cancer: insights into diagnosis and management
    Qin, Chunxia
    Song, Yangmeihui
    Gai, Yongkang
    Ruan, Weiwei
    Liu, Qingyao
    Liu, Fang
    Zheng, Danzha
    Zhang, Peng
    Liu, Hongli
    Zhang, Tao
    Tao, Kaixiong
    Lan, Xiaoli
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (12) : 4228 - 4240
  • [5] 68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-FAPI PET Observational Trial
    Kessler, Lukas
    Hirmas, Nader
    Pabst, Kim M.
    Hamacher, Rainer
    Ferdinandus, Justin
    Schaarschmidt, Benedikt M.
    Milosevic, Aleksandar
    Nader, Michael
    Umutlu, Lale
    Uhl, Waldemar
    Reinacher-Schick, Anke
    Lugnier, Celine
    Witte, David
    Niedergethmann, Marco
    Herrmann, Ken
    Fendler, Wolfgang P.
    Siveke, Jens T.
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (12) : 1910 - 1917
  • [6] Feasibility of 68Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT in Light-Chain Cardiac Amyloidosis
    Wang, Xuezhu
    Guo, Yubo
    Gao, Yajuan
    Ren, Chao
    Huang, Zhenghai
    Liu, Bowei
    Li, Xiao
    Chang, Long
    Shen, Kaini
    Ding, Haiyan
    Zhang, Hui
    Tian, Zhuang
    Hacker, Marcus
    Zhang, Shuyang
    Wang, Yining
    Li, Jian
    Li, Xiang
    Huo, Li
    JACC-CARDIOVASCULAR IMAGING, 2022, 15 (11) : 1960 - 1970
  • [7] Gallium68-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET/CT as an Alternative to Fluoro18-Fluorodeoxyglucose (18F-FDG) PET/CT: Discussion in a Case of Metastatic Adenocarcinoma of Pancreas
    Kumar, Abhishek
    Kumar, Bhola
    Upadhyay, Amitabh Kumar
    Muthu, G. S.
    Mitra, Sujata
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (12)
  • [8] 68Ga-FAPI-04 PET/CT in Assessment of Fibroblast Activation in Keloids: A Prospective Pilot Study
    Wang, Jiarou
    Yu, Nanze
    Wang, Guochang
    Wang, Rongxi
    Li, Linlin
    Jiang, Yuanyuan
    Sui, Huimin
    Sun, Yixin
    Li, Zhijin
    Long, Xiao
    Zhu, Zhaohui
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (01) : 16 - 22
  • [9] Performance of 68Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT in Evaluation of Erdheim-Chester Disease: A Comparison with 18F-FDG PET/CT
    Ma, Jiangyu
    Yang, Qiao
    Huo, Li
    Dai, Jiawen
    Niu, Na
    Cao, Xinxin
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (09) : 1385 - 1391
  • [10] Diagnostic Accuracy of [68Ga]Ga Labeled Fibroblast-Activation Protein Inhibitors in Detecting Head and Neck Cancer Lesions Using Positron Emission Tomography: A Systematic Review and a Meta-Analysis
    Rizzo, Alessio
    Miceli, Alberto
    Racca, Manuela
    Bauckneht, Matteo
    Morbelli, Silvia
    Albano, Domenico
    Dondi, Francesco
    Bertagna, Francesco
    Galizia, Danilo
    Muoio, Barbara
    Annunziata, Salvatore
    Treglia, Giorgio
    PHARMACEUTICALS, 2023, 16 (12)